Receipt of perioperative blood transfusion after surgery for renal cell carcinoma is associated with a higher risk of tumor recurrence, progression, and death. READ MORE
The updated 2017 AUA guidelines for localized kidney cancer have been released, focusing on functional outcomes in relation to multiple treatment options.
The first evidence-based guidelines for the use of immunotherapies in the treatment of patients with RCC have now been published by the Society for ImmunoTherapy of Cancer.
Some patients with metastatic renal cell carcinoma can safely undergo active surveillance and delay the start of systemic therapy.
A wait-and-see approach, rather than immediate treatment, may be appropriate for certain patients with advanced kidney cancer.
Research in Review
Outcomes of Kidney-Sparing Surgery and Radical Nephroureterectomy Similar for Patients With Kidney Cancer
Kidney-sparing surgery and radical nephroureterecttomy lead to similar survival for low-grade and noninvasive upper tract urothelial carcinoma (UTUC).
Certain patients with metastatic renal cell carcinoma can (RCC) safely undergo active surveillance before initiating systemic treatment.
Researchers co-lead by Maxine Sun, PhD, and Nawar Hanna, MD, Dana-Farber and Brigham and Women’s, conducted a study evaluating the utilization rates of cytoreductive nephrectomy and how use of the technique affected survival in patients receiving targeted therapies for metastatic renal cancer.
Patients with renal cell carcinoma may continue to benefit from treatment with nivolumab even after the disease has progressed, according a study published JAMA Oncology.